May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Blood Brain Barrier Disruption Maculopathy
A. Galor; S. J. Ference; A. D. Singh; M. S. Lee; G. H. J. Stevens; V. L. Perez; D. M. Peereboom
Author Affiliations & Notes
  • A. Galor
    Ophthalmology, Wilmer Eye Institute, Baltimore, Maryland
  • S. J. Ference
    Brain Tumor Institute,
    Cleveland Clinic, Cleveland, Ohio
  • A. D. Singh
    Cole Eye Institute,
    Cleveland Clinic, Cleveland, Ohio
  • M. S. Lee
    Department of Neuro-opthalmology, University of Minnesota, Minneapolis, Minnesota
  • G. H. J. Stevens
    Brain Tumor Institute,
    Cleveland Clinic, Cleveland, Ohio
  • V. L. Perez
    Ophthalmology,
    Cleveland Clinic, Cleveland, Ohio
  • D. M. Peereboom
    Brain Tumor Institute,
    Cleveland Clinic, Cleveland, Ohio
  • Footnotes
    Commercial Relationships A. Galor, None; S.J. Ference, None; A.D. Singh, None; M.S. Lee, None; G.H.J. Stevens, None; V.L. Perez, None; D.M. Peereboom, None.
  • Footnotes
    Support Research To Prevent Blindness
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 5237. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Blood Brain Barrier Disruption Maculopathy
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      A. Galor, S. J. Ference, A. D. Singh, M. S. Lee, G. H. J. Stevens, V. L. Perez, D. M. Peereboom; Blood Brain Barrier Disruption Maculopathy. Invest. Ophthalmol. Vis. Sci. 2007;48(13):5237.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose:: To report on the development of visually significant maculopathy associated with blood brain barrier disruption therapy for the treatment of CNS lymphoma.

Methods:: Chart review of twenty patients undergoing blood brain barrier disruption therapy for treatment of CNS lymphoma at the Cleveland Clinic. Patients with documented maculopathy included in analysis.

Results:: Seven of thirteen patients (54%) were identified with new macular RPE changes after blood brain barrier disruption treatment which developed at a rate of 0.30 per person-year. The RPE changes consisted of fine clumps of hyperpigmentation in the foveal region associated with variable degrees of RPE loss. These changes were bilateral but often asymmetric. Two patients had decreased visual acuity due to maculopathy. One patient had documented progression of maculopathy after completion of treatment.

Conclusions:: Maculopathy is frequent after blood brain barrier disruption therapy.

Keywords: oncology • macula/fovea 
© 2007, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2025 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept